PCSK9 and acute coronary syndrome: Navarese et al. [51] explored platelet aggregation and the onset of major adverse cardiovascular events (MACEs) in PCSK9-REACT patients with acute coronary syndrome who were receiving prasugrel or ticagrelor and P2Y12 inhibitors and undergoing percutaneous coronary intervention (PCI).